Helen Collins, a director at Enliven Therapeutics, Inc., has filed a notice to sell 15,000 shares of the company’s common stock. This sale is part of a previously adopted 10b5-1 selling plan, which allows executives to sell shares at predetermined times to avoid allegations of insider trading.
The filing, dated October 19, 2026, indicates that Collins plans to sell the shares through Jefferies LLC, a well-known brokerage firm. The aggregate market value of the shares to be sold is approximately $559,800. This sale comes after Collins sold 5,000 shares on August 17, 2026, and another 5,000 shares on September 17, 2026, for gross proceeds of $292,930 and $251,753.75, respectively.
Background
Enliven Therapeutics, Inc. operates in the pharmaceutical preparations sector, focusing on developing innovative therapies. The company is based in Burlingame, California, and is publicly traded on NASDAQ under the SEC file number 001-39247. The company was formerly known as IMARA Inc. before its name change in April 2016.
What the Filing Says
The SEC filing reveals that Collins acquired the shares to be sold through stock options granted by Enliven Therapeutics on August 9, 2022. The filing states, “All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 10/19/2025.” This plan allows for the sale of shares while ensuring compliance with securities regulations.
Impact
This sale may affect the perception of Enliven Therapeutics among investors, as insider selling can sometimes lead to speculation about the company's future. However, such transactions are common among executives managing their compensation and investment strategies. The pharmaceutical industry may also see similar actions from other executives as they navigate stock options and market conditions.
What's Next
The filing does not say what happens next. However, it is expected that Collins will continue to follow her selling plan as outlined, which may involve additional sales in the future.